Price Action To Observe: A Reversal for Novo Nordisk A S (ADR) Is Not Near. The Stock Declines Again

Price Action To Observe: A Reversal for Novo Nordisk A S (ADR) Is Not Near. The Stock Declines Again

The stock of Novo Nordisk A S (ADR) (NYSE:NVO) is a huge mover today! About 1.81M shares traded hands. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 29.23% since March 10, 2016 and is downtrending. It has underperformed by 36.75% the S&P500.
The move comes after 9 months negative chart setup for the $79.19B company. It was reported on Oct, 13 by We have $36.63 PT which if reached, will make NYSE:NVO worth $5.54 billion less.

Analysts await Novo Nordisk A S (ADR) (NYSE:NVO) to report earnings on November, 3. They expect $0.56 EPS, up 14.29% or $0.07 from last year’s $0.49 per share. NVO’s profit will be $1.13B for 17.58 P/E if the $0.56 EPS becomes a reality. After $0.60 actual EPS reported by Novo Nordisk A S (ADR) for the previous quarter, Wall Street now forecasts -6.67% negative EPS growth.

Novo Nordisk A S (ADR) (NYSE:NVO) Ratings Coverage

Out of 10 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 3 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 30% are positive. Novo Nordisk (ADR) has been the topic of 10 analyst reports since August 28, 2015 according to StockzIntelligence Inc. On Monday, October 19 the stock rating was upgraded by Jyske Bank to “Strong Buy”. The firm has “Outperform” rating given on Tuesday, September 13 by BNP Paribas. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) has “Equal-Weight” rating given on Thursday, September 1 by Morgan Stanley. The firm has “Hold” rating by HSBC given on Wednesday, August 31. The rating was downgraded by JP Morgan to “Neutral” on Friday, September 9. Leerink Swann initiated the shares of NVO in a report on Friday, August 28 with “Market Perform” rating. UBS downgraded the stock to “Sell” rating in Monday, February 8 report. The rating was initiated by Piper Jaffray on Friday, September 23 with “Neutral”. Goldman Sachs upgraded the shares of NVO in a report on Monday, February 15 to “Conviction Buy” rating. The firm has “Hold” rating given on Friday, August 28 by Zacks.

According to Zacks Investment Research, “Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world’s largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.”

More notable recent Novo Nordisk A S (ADR) (NYSE:NVO) news were published by: which released: “DOW JONES, A NEWS CORP COMPANY” on February 11, 2011, also with their article: “/quotes/zigman/3870025/realtime” published on July 03, 2009, published: “Novo Nordisk Earnings Preview: What to Expect” on August 02, 2016. More interesting news about Novo Nordisk A S (ADR) (NYSE:NVO) were released by: and their article: “Novo Nordisk A/S (ADR): Diabetic Leader Gets Yet Another FDA Approval” published on May 26, 2016 as well as‘s news article titled: “Why American Airlines Group Inc (AAL), Novo Nordisk A/S (ADR) (NVO) and …” with publication date: June 14, 2016.

NVO Company Profile

Novo Nordisk A/S, incorporated on November 28, 1931, is a healthcare company. The Firm is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business divisions include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment